Story perspectives

FDA Approves Tec-Dara: 83% Disease Progression Reduction for Myeloma

3/6/2026

Summary

Story summary

On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved Tec-Dara, a teclistamab–daratumumab combination, for adults with relapsed or refractory multiple myeloma after one prior therapy.
The approval came 55 days after filing and falls under the FDA's National Priority Voucher program.
Tec-Dara reduced the risk of disease progression or death by 83% versus standard care and carries risks including cytokine release syndrome and neurologic toxicity.

1 of 1

Story summary

On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved Tec-Dara, a teclistamab–daratumumab combination, for adults with relapsed or refractory multiple myeloma after one prior therapy.
The approval came 55 days after filing and falls under the FDA's National Priority Voucher program.
Tec-Dara reduced the risk of disease progression or death by 83% versus standard care and carries risks including cytokine release syndrome and neurologic toxicity.